Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10951309 | 0.88 | PIK3CD (0.47) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL28005010 | 0.83 | PIK3CD (0.43) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL25633842 | 0.82 | KMT2A (0.43) | PIK3CDKMT2ATSHRSMN1; SMN2POLB | |
| SCHEMBL7649491 | 0.79 | PIK3CD (0.58) | PIK3CDKMT2ATSHRMEN1PKM | |
| SCHEMBL25985239 | 0.77 | SMN1; SMN2 (0.45) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL25985509 | 0.77 | PIK3CD (0.43) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL3430972 | 0.77 | PIK3CD (0.66) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL28189863 | 0.75 | TSHR (0.49) | PIK3CDKMT2ATSHRMEN1PKM | |
| SCHEMBL6938181 | 0.74 | KMT2A (0.50) | PIK3CDKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL20886713 | 0.74 | PIK3CD (0.56) | PIK3CDKMT2ATSHRMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672781-B2 | Metaxalone formulations | PRANA BIOSCIENCES INC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672781-B2 | Metaxalone formulations | PRANA BIOSCIENCES INC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210212995-A1 | METAXALONE FORMULATIONS | PRANA BIOSCIENCES INC (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672781-B2 | Metaxalone formulations | MTX1, MLX, LPXN | PIK3CD 2770/4885KMT2A 2401/4885TSHR 3995/4885 |
| US-20210212995-A1 | METAXALONE FORMULATIONS | MTX1, MLX, LPXN | PIK3CD 2770/4885KMT2A 2401/4885TSHR 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.